Ease-it Spray for the Treatment of Fire Ant Stings NCT00435552

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Details — Status: Completed

Study information
Verified date	January 2007
Source	C.R.Darnall Army Medical Center
Contact	n/a
Is FDA regulated	No
Health authority	United States: Federal Government
Study type	Interventional

The application of Ease-it Spray will alleviate pain secondary to fire ant stings more quickly than placebo.

Recruitment information / eligibility
Status	Completed
Enrollment	0
Est. completion date
Est. primary completion date
Accepts healthy volunteers
Gender	Both
Age group	18 Years to 60 Years
Eligibility	Inclusion Criteria: - AD soldier in US Army - Ages 18-60 - Volunteer - Absence of serious medical condition - Past allergic reactions - Asthma - History of (h/o) IFA sting Exclusion Criteria: - Inability to provide informed consent - Known h/o hymenoptera allergic reaction - Allergy to any component of the treatments - Inability to follow-up - Active medical condition - Pregnancy

Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Procedure:
• Ease-It Spray

Locations
Country	Name	City	State
n/a

Sponsors *(1)*
Lead Sponsor	Collaborator
C.R.Darnall Army Medical Center

See also
	Status	Clinical Trial	Phase
	Completed	`NCT02503800` - The Significance of Blood-tryptase and c-Kit Mutation in Insect Venom Immunotherapy